

Detection of Subclinical Cardiac Damage by Echocardiography in a Hypertensive Population with a High Prevalence of Obesity: Discrepancies According to the Indexing Method Used

Detección de daño cardíaco subclínico mediante ecocardiografía en una población de hipertensos con alta prevalencia de obesidad: discrepancias observadas según el método de indexación empleado.

CAROLINA M. TRAVETTO¹, LAURA V. ARGENTO¹, MTSAC.

ABSTRACT

Background: Allometric height-based indexing improves the detection of cardiac target organ damage in overweight/obese hypertensives versus body surface area-based indexing; however, its use is not common in daily practice.

Objective: To compare the prevalence of left ventricular hypertrophy and/or left atrial enlargement according to the echocardiographic indexing method used, and to estimate the level of agreement and the percentage of reclassified subjects.

Methods: Descriptive, observational and prospective study. We included 150 adults with hypertension. Left ventricular mass was indexed to body surface area and height^{2.7}. Maximum left atrial volume was indexed to body surface area and height². Subgroup analysis was performed according to body mass index categories. The degree of agreement between methods was evaluated with the Kappa index (k).

Results: Mean age was 57.1 years, 62.7% were women, 58.7% were obese. The prevalence of ventricular hypertrophy and left atrial enlargement was higher with height-based indexing. The level of agreement for the detection of left ventricular hypertrophy with both indices was considerable (k=0.76) but poor for the detection of left atrial enlargement (k=0.23). The discrepancy between the methods was greater at higher body mass index. One third of the subjects were reclassified regarding the presence of cardiac target organ damage by using height-based indexing.

Conclusion: Cardiac structures indexed to body surface area underestimate the presence of target organ damage in overweight/obese hypertensive subjects. We suggest considering the systematic use of height-based indexing in hypertensive subjects.

Key words: Obesity - Hypertension - Echocardiography - Indexing methods - Left ventricular hypertrophy - Cardiovascular diagnostic techniques

RESUMEN

Introducción: Los índices alométricos basados en la altura mejoran la detección de daño de órgano blanco cardíaco en hipertensos con sobrepeso/obesidad versus la indexación por superficie corporal; sin embargo su uso no es habitual en la práctica diaria.

Objetivo: Comparar la prevalencia de hipertrofia ventricular izquierda y/o agrandamiento auricular izquierdo según el método de indexación ecocardiográfico empleado, y estimar el nivel de concordancia observado y el porcentaje de individuos que resulta reclasificado.

Material y métodos: Estudio descriptivo, observacional y prospectivo. Se incluyeron 150 adultos con hipertensión arterial. La masa ventricular izquierda se indexó por superficie corporal y altura^{2.7}. El volumen auricular izquierdo máximo se indexó por superficie corporal y altura². Se realizó análisis por subgrupos según categorías de índice de masa corporal. El grado de concordancia entre métodos se evaluó con el índice Kappa (k).

Resultados: Edad media 57,1 años, 62,7% mujeres, 58,7% con obesidad. La prevalencia de hipertrofia ventricular y agrandamiento auricular izquierdo fue mayor con la indexación basada en la altura. El nivel de concordancia para la detección de hipertrofia ventricular izquierda con ambos índices fue considerable (k=0,76) y pobre para la detección de agrandamiento auricular izquierdo (k=0,23), con mayor discrepancia entre métodos a mayor índice de masa corporal. Un tercio de los sujetos fue reclasificado respecto de la presencia de daño cardíaco empleando la indexación basada en la altura.

Conclusión: La indexación de estructuras cardíacas por superficie corporal subestima la presencia de daño de órgano blanco en hipertensos con sobrepeso/obesidad. Sugerimos considerar el uso sistemático de la indexación basada en la altura en sujetos con hipertensión arterial.

Palabras claves: Obesidad - Hipertensión - Ecocardiografía - Métodos de indexación - Hipertrofia ventricular izquierda - Técnicas de diagnóstico cardiovascular

REV ARGENT CARDIOL 2025;93:6-13. <https://doi.org/10.7775/rac.v93.i1.20852>

Received: 01/16/2025 – Accepted: 02/03/2025

Correspondence: Carolina M. Travetto, RO del Uruguay 224, Morón, Provincia de Buenos Aires, Argentina. E-mail: carolinatravetto@hotmail.com

Financing: The study was conducted without external financing.

This article won the Dr. Oscar Orías Award - special mention "Accesit" at the 50th Argentine Congress of Cardiology.



<https://creativecommons.org/licenses/by-nc-sa/4.0/>

©Revista Argentina de Cardiología

¹ Cardiology Department, Sanatorio Clínica Modelo de Morón, Province of Buenos Aires, Argentina

INTRODUCTION

Early detection of subclinical cardiac target organ damage (TOD) is essential for the stratification of the overall cardiovascular risk in hypertensive patients and has a direct impact on the appropriateness of treatment, the target blood pressure (BP) value and the time to achieve it, as well as the choice of the drug class expected to provide the greatest therapeutic benefit. (1,2)

Normalization of cardiac chambers measurements using allometric height-based indexing (AHI) improves the detection of TOD in subjects with hypertension (HT) and overweight or obesity compared to body surface area-based indexing (BSAI). Although this has been included in international guidelines, (3-8) its use in clinical practice is not widespread. This may be due to different factors, including lack of knowledge, habit or technical difficulties because of the lack of suitable calculation packages for this population in most echocardiography equipment.

Both HT and obesity promote left ventricular remodelling and hypertrophy (LVH) independently and synergistically. (9-12) Increased ventricular mass in non-hypertensive subjects is related to weight and body mass index (BMI), (13, 14) and the presence of obesity-related LVH is an independent predictor of cardiovascular events. (15) Likewise, obesity per se may promote atrial chamber enlargement. In a subanalysis of the MONICA/KORA study, obesity was the most important independent predictor of the incidence of left atrial enlargement (LAE) after aging. (16)

In view of today's obesity pandemic, which in some regions has reached a prevalence of almost 60% in populations over 20 years old, (17) and in which 75% of the incidence of HT is directly related to overweight, (18) we wondered how often the use of AHI, compared to BSAI leads to the reclassification of subjects in terms of the presence of TOD according to their degree of obesity. This knowledge is important to measure the degree of error that results from failing to use the appropriate indices.

OBJECTIVES

To compare the prevalence of TOD, defined as LVH and/or LAE, according to the echocardiographic indexing method used, and to estimate the level of agreement between the methods and the percentage of subjects who are reclassified according to their degree of obesity.

METHODS

Between January 2020 and December 2021, adults over 18 years old with a diagnosis of HT either under drug treatment or non-drug treatment and referred to a Doppler echocardiography were prospectively assessed. Subjects with any other cardiovascular history or relevant comorbidity were excluded, except for cardiovascular risk factors, known secondary HT, pregnancy, echocardiographic findings consistent with significant valvular heart disease, structural heart disease of other origin or systolic dysfunction. A complete

medical history was taken from all patients and weight, height (H) and BP were recorded. Body surface area (BSA) was estimated using the Du Bois and Du Bois formula: $BSA (m^2) = 0.007184 \times H (cm)^{0.725} \times weight (kg)^{0.42}$. BMI was calculated according to the formula: $BMI (kg/m^2) = Weight (kg) / [H (m)]^2$. BP was measured in a seated position, after a 5-minute rest, with an automatic sphygmomanometer (Omron MODEL Hem 7142, Omron Corporation). Two consecutive measurements were obtained, with an interval of 2 minutes between each one, and the values were averaged. Controlled BP at the time of the study was defined as the presence of systolic BP <140 mmHg and diastolic BP <90 mmHg. Doppler echocardiography was performed immediately after BP measurement.

Echocardiography

A Mindray M9 equipment with SP5-1s probe was used. Cardiac chambers diameters and remodelling patterns were evaluated according to the recommendations of the American Society of Echocardiography Guidelines. (3, 4) M-mode was used to measure left ventricular (LV) diameters. LV ejection fraction (LVEF) was estimated using the biplane Simpson method. Left ventricular mass (LVM) was calculated with the Devereux formula and indexed to BSA and $H^{2.7}$. Relative wall thickness (RWT) was calculated with the formula $2 \times LV \text{ posterior wall thickness in diastole} / LV \text{ end-diastolic diameter (LVEDD)}$, and a value ≥ 0.42 was considered increased RWT. Left atrial (LA) volumes were assessed by using the modified biplane Simpson's method from apical 2- and 4-chamber views. In each case, 2 measurements were obtained and averaged. Absolute values were indexed to BSA and H^2 . Table 1 shows the cut-off values used for each determination. The choice of these allometric indices over others was based on the evidence supporting their use and the recommendations of international guidelines. (5-8)

Statistical analysis

Qualitative variables are presented as absolute frequency and percentage, and quantitative variables are presented as median and interquartile range (IQR 25-75) or mean and standard deviation (SD), according to data distribution. The distribution of variables was analysed in the total population and by BMI subgroups (<25, 25-29.9, 30-34.9, $\geq 35 \text{ kg/m}^2$). Comparison of discrete variables was performed with the chi-square test with Fisher's correction. Comparison of continuous variables was performed with Kruskal-Wallis or ANOVA method, as appropriate. Comparison of the prevalence of LVH/LAE/TOD between both methods was performed with the paired binomial test. The degree of agreement for the classification of presence/absence of subclinical cardiac TOD between different indexing methods was evaluated with Cohen's Kappa index (k), considering that a value of 1 represents perfect agreement in the classification of each case and a value of 0 indicates agreement no better than that expected by chance. A statistical significance level of 0.05 (bilateral test) was used in the hypothesis tests. Data processing was performed with EpiInfo version 7.2.5.0 (CDC, Atlanta) and EpiDat version 4.2 (Conselleria de Sanidade, Xunta de Galicia, Spain; PAHO, Washington; Universidad CES, Colombia. Available at: <http://www.sergas.es/Saude-publica/EPIDAT>).

Ethical considerations

The study was evaluated by an independent Research Ethics Committee. Informed consent was obtained from participants prior to enrolment. The research was conducted in accordance with the principles of the Declaration of Helsinki.

Table 1. Cut-off limits used in indexed echocardiographic measurements

| Variable | Men | Women | Reference |
|--|--------|--------|-----------|
| LVM/BSA (g/m ²) | ≤ 115 | ≤ 95 | 3, 4 |
| LVM/H ^{2.7} (g/m ^{2.7}) | ≤ 50 | ≤ 47 | 5-8 |
| LAV/BSA (mL/m ²) | ≤ 34 | ≤ 34 | 5-8 |
| LAV/H ² (mL/m ²) | ≤ 18.5 | ≤ 16.5 | 5-8 |

BSA: body surface area; H: height; LAV: maximum left atrial volume; LVM: left ventricular mass

RESULTS

A total of 150 subjects were included. Mean age was 57.1 years (SD 12.6); 62.7% were women, 58.7% were obese; 94% were receiving drug treatment. Tables 2 and 3 show the clinical and echocardiographic characteristics of the population. Non-indexed and H^{2.7}-indexed LVM, and non-indexed or H²-indexed maximum left atrial volume (LAV) presented higher values in the groups with higher obesity, while BSA-indexed LVM and LAV showed no differences between the groups according to BMI.

The presence of LVH ranged from 22% using BSAI to 25.3% using AHI ($p = 0.266$), with a greater difference between the methods at higher BMI (Figure 1). The overall agreement for classification according to the presence or absence of LVH was substantial ($k = 0.76$), with the highest level of agreement in the group with BMI 25-29.9 and the lowest level of agreement in the group with BMI 30-34.9 (Table 4 and Figure 2). The use of LVM indexed to H^{2.7}, compared to BSAI, resulted in the reclassification regarding the presence of LVH in 13 subjects (8.6%).

The greatest discrepancy between the methods was recorded in the detection of LAE, which ranged from 11.3% using BSAI to 49.3% using AHI ($p < 0.001$), with a greater difference in prevalence between the groups at higher BMI (Figure 1). The overall agreement between the methods for LAE detection was low ($k = 0.23$), with the exception of the group with BMI ≤ 25 , which showed a substantial level of agreement ($k = 0.85$). In the rest of the groups, the level of agreement was poor and the greatest discrepancy was observed in the group with BMI ≥ 35 (Table 4 and Figure 2). Using AHI for LAV resulted in the reclassification of 57 subjects (38%). In all discordant cases, by using AHI, LAE was identified in subjects classified as not having LAE according to BSAI.

When comparing the prevalence of TOD (LVH and/or LAE) using either BSAI or AHI, a detection rate of 26% and 56%, respectively, was observed ($p < 0.001$), with a greater difference between methods in the higher BMI subgroups (Figure 1). The overall level of agreement between the methods for the detection of TOD was moderate ($k = 0.38$); the group with BMI ≤ 25 showed a substantial level of agreement ($k = 0.85$), in the remaining groups the level of agreement was low, and the greatest discrepancy was observed in the group with BMI ≥ 35 (Table 4 and Figure 2).

DISCUSSION

The results of this study show that the presence of subclinical cardiac TOD may remain undetected in a high proportion of overweight or obese hypertensive subjects when using BSAI instead of AHI. The level of agreement between both methods for the detection of TOD was poor, lower for the detection of LAE than LVH, and with greater discrepancies at higher BMI. In the group of subjects without overweight, the level of agreement between the two methods was high, both for the detection of LVH and LAE, which leads us to believe that in hypertensive populations with a high prevalence of overweight or obesity, such as the one included in the present study, the global use of AHI may be convenient.

Numerous studies have evaluated the impact of the indexing methods used to detect LVH, both in selected cohorts of subjects with HT and in population-based studies. The frequencies reported vary considerably depending on the characteristics of the population included and the cut-off values used to define LVH. When reviewing the studies that compared BSAI and AHI, a consistent finding was the higher detection rate of LVH using AHI, and the difference was greater when the proportion of obese subjects in the included sample was higher. (19-22) Using AHI for LVM has shown to be more predictive of cardiovascular events than BSAI at follow-up in overweight or obese hypertensive subjects (19,22,23). Gosse et al. reported in a cohort of 763 hypertensive subjects that LVM (g/H^{2.7}) before the initiation of treatment was the strongest predictor of cardiovascular events at follow-up, above other risk factors, such as age, systolic BP, and smoking, as well as the second strongest predictor of all-cause death, after age. Detection of LVH at follow-up had a similar predictive value, whereas regression of LVH was associated with lower cardiovascular risk. (23) In the study by Kuznetsova et al., the presence of LVH according to the H^{2.7} method had the highest prognostic value for fatal or non-fatal cardiovascular events compared to other indexing methods. (19) That study also evaluated the level of agreement for the detection of LVH using different indexing methods according to the degree of obesity. Similar to this study, the difference in the detection of LVH between the two methods was small in the subgroup of non-overweight, but it increased sharply in the subgroups of overweight or obese subjects, with a difference in

Tabla 2. Clinical characteristics of the population included in the study by body mass index (BMI) categories

| | Global n = 150 | <25 kg/m ² n = 21 | 25-29.9 kg/m ² n = 41 | 30-34.9 kg/m ² n = 58 | ≥35 kg/m ² n = 30 | p |
|--------------------------------------|-------------------|---------------------------------|-------------------------------------|-------------------------------------|---------------------------------|---------|
| Age (years) | 57.10 (12.66) | 60.57 (15.35) | 56.00 (11.40) | 57.84 (12.84) | 54.73 (11.88) | 0.389 |
| Women | 94 (62.67%) | 16 (76.19%) | 23 (56.10%) | 32 (55.17 %) | 23 (76.67%) | 0.097 |
| Diabetes mellitus | 39 (26.00%) | 1 (4.76%) | 9 (21.95%) | 17 (29.31%) | 12 (40.00%) | 0.034 |
| Current or past smoking | 65 (43.33%) | 7 (33.33%) | 17 (41.46%) | 24 (41.38%) | 17 (56.67%) | 0.365 |
| Dyslipidemia | 78 (52.00%) | 16 (76.19%) | 17 (41.46%) | 33 (56.90%) | 12 (40.00%) | 0.028 |
| Weight (kg) | 84.37 (16.33) | 61.23 (8.31) | 77.31 (9 .12) | 88 .87 (11.08) | 101.48 (12.88) | < 0.001 |
| Height (m) | 1.64 (0.09) | 1.63 (0.09) | 1.66 (0.09) | 1.66 (0.10) | 1.60 (0.08) | 0.039 |
| BSA (m ²) | 1.90 (0.21) | 1.66 (0.16) | 1.85 (0.17) | 1.96 (0.18) | 2.01 (0.16) | < 0.001 |
| BMI (kg/m ²) | 31.22 (5.62) | 22.94 (1.57) | 27.7 (1.27) | 32.3 (1.48) | 39.7 (3.20) | < 0.001 |
| Diagnosis of HT older than 1 year | 115 (76.67%) | 16 (76.19%) | 19 (70.73%) | 47 (81.03%) | 23 (76.67%) | 0.698 |
| Drug treatment | 141 (94.00%) | 19 (90.48%) | 36 (87.80%) | 57 (98.28%) | 29 (96.67%) | 0.138 |
| SBP (mmHg) | 136.14 (15.53) | 138.66 (19.80) | 135.78 (13.09) | 136.06 (14.89) | 135.00 (17.05) | 0.866 |
| DBP (mmHg) | 85.61 (9.03) | 85.38 (9.22) | 86.31 (8.69) | 85.03 (9.70) | 85.93 (8.35) | 0.912 |
| MBP (mmHg) | 102.38 (9.45) | 103.10 (10.51) | 102.77 (7.88) | 101.91 (9.97) | 102.25 (10.05) | 0.952 |
| Pulse pressure (mmHg) | 50.52 (14.39) | 53.28 (18.56) | 49.46 (14.26) | 51.03 (13.3) | 49.06 (13.67) | 0.715 |
| Controlled BP | 65 (43.33%) | 9 (42.86%) | 16 (39.02%) | 25 (43.10%) | 15 (50.00%) | 0.836 |
| HR (bpm) | 73.88 (13,31) | 72.14 (10,38) | 71.73 (12.73) | 75.08 (15.21) | 75.7 (11.98) | 0.486 |

BMI: body mass index; BP: blood pressure; BPM: beats per minute; BSA: body surface area; DBP: diastolic blood pressure; HR: heart rate; HT: hyper-tension; MBP: mean blood pressure; SBP: systolic blood pressure.

Quantitative variables are expressed as mean (SD) and categorical variables as absolute frequency (%).


Tabla 3. Echocardiographic characteristics of the population included in the study by body mass index categories

| | Global n = 150 | <25 kg/m ² n = 21 | 25-29.9 kg/m ² n = 41 | 30-34.9 kg/m ² n = 58 | ≥35 kg/m ² n = 30 | p |
|--|------------------------|---------------------------------|-------------------------------------|-------------------------------------|---------------------------------|---------|
| LVDD (cm) | 4.63 (4.34-4.99) | 4.44 (4.30-4.76) | 4.59 (4.23-4.94) | 4.64 (4.40-4.90) | 4.89 (4.50-5.57) | 0.032 |
| IVS (cm) | 1.03 (0.20) | 0.87 (0.19) | 1.05 (0.19) | 1.05 (0.20) | 1.07 (0 .18) | 0.001 |
| PW (cm) | 0.89 (0.16) | 0.77 (0.18) | 0.88 (0.16) | 0.93 (0.15) | 0.91 (0.15) | 0.001 |
| RWT | 0.38 (0.07) | 0.34 (0.07) | 0.39 (0.07) | 0.40 (0.08) | 0.37 (0.06) | 0.004 |
| LVM (gr) | 150.03 (124.22-192.02) | 115.87 (90.97-152.15) | 139.19 (129.10-177.78) | 159.23 (125.67-192.02) | 171.49 (135.33-221.08) | < 0.001 |
| LVM/ BSA (g/m ²) | 78.05 (66.60-98.64) | 67.68 (58.16-84.32) | 76.71 (68.58-98.64) | 80.43 (65.68-93.30) | 80.25 (69.74-110.54) | 0.117 |
| LVM/H ^{2.7} (g/m ^{2.7}) | 38.80 (33.04-48.47) | 29.02 (24.94-38.78) | 36.19 (32.71-44.44) | 39.38 (34.33-47.74) | 48.30 (39.08-63.71) | < 0.001 |
| LVEF (%) | 63.06 (4.47) | 62.55 (3.54) | 64.37 (4.66) | 62.04 (4.10) | 63.68 (5.10) | 0.065 |
| LAV (mL) | 47.80 (12.30) | 41.16 (11.63) | 46.40 (10.86) | 49.18 (12.49) | 51.84 (12.64) | 0.013 |
| LAV/BSA (mL/m ²) | 25.28 (6.19) | 25.38 (8.15) | 25.09 (5.22) | 25.15 (6.34) | 25.74 (5.85) | 0.973 |
| LAV/H ² (mL/m ²) | 17.64 (4.48) | 15.42 (4.53) | 16.65 (3.19) | 17.92 (4.64) | 20.07 (4.67) | < 0.001 |

BSA: body surface area; H: height; IVS: interventricular septum; LAV: maximum left atrial volume; LV DD: left ventricular diastolic diameter; LVEF: left ventricular ejection fraction; LVM: left ventricular mass; PW: posterior wall; RWT: relative wall thickness.

Quantitative variables are expressed as mean (SD) or median (IQR 25-75) and categorical variables as absolute frequency (%).

Fig. 1. Prevalence of left ventricular hypertrophy (A), left atrial enlargement (B) or subclinical cardiac target organ damage (C) by indexing method and body mass index category



AHI: allometric height-based indexing; BMI: body mass index; BSAI: body surface indexing; LAE: left atrial enlargement; LVH: left ventricular hypertrophy; Prev diff: difference in prevalence between indexing methods; TOD: subclinical cardiac target organ damage (LVH and/or LAE). The p value presented to the right of each row corresponds to the comparison of the prevalence observed between both methods in the paired analysis by body mass index subgroup.

Tabla 4. Level of agreement for the determination of presence or absence of subclinical cardiac target organ damage using body surface area-based indexing or allometric height-based indexing

| BSAI vs AHI measurement | BMI subgroup | Agreement | k | 95% CI | Maximum k value |
|-------------------------|---------------------------|-----------|------|-------------|-----------------|
| LVH | Global | 91.3% | 0.76 | 0.63-0.88 | 0.82 |
| | <25 kg/m ² | 95.2% | 0.77 | 0.35 -1 | 0.90 |
| | 25-29.9 kg/m ² | 95.1% | 0.82 | 0.60-1 | 0.90 |
| | 30-34.9 kg/m ² | 89.6% | 0.68 | 0.45-0.91 | 0.79 |
| | ≥35 kg/m ² | 86.6% | 0.73 | 0.5-0.96 | 0.73 |
| LAE | Global | 62% | 0.23 | 0.13-0.33 | 0.33 |
| | <25 kg/m ² | 95.2% | 0.85 | 0.59-1 | 0.90 |
| | 25-29.9 kg/m ² | 63.4% | 0.18 | -0.006-0.37 | 0.35 |
| | 30-34.9 kg/m ² | 56.9% | 0.16 | 0.02-0.29 | 0.27 |
| | ≥35 kg/m ² | 46.6% | 0.15 | 0.005-0.30 | 0.16 |
| TOD | Global | 67.3% | 0.38 | 0.26-0.49 | 0.40 |
| | <25 kg/m ² | 95.2% | 0.85 | 0.59-1 | 0.90 |
| | 25-29.9 kg/m ² | 68.2% | 0.33 | 0.09-0.58 | 0.42 |
| | 30-34.9 kg/m ² | 63.7% | 0.33 | 0.14-0.51 | 0.35 |
| | ≥35 kg/m ² | 53.3% | 0.18 | 0.005-0.36 | 0.23 |

AHI: allometric height-based indexing; BMI: body mass index; BSAI: body surface area indexing; H: height; k: Kappa index; LAE: left atrial enlargement; LVH: left ventricular hypertrophy; TOD: subclinical cardiac target organ damage (LVH and/or LAE)




Fig. 2. Graphical representation of the Kappa index for the determination of presence or absence of left ventricular hypertrophy (A), left atrial enlargement (B) and subclinical cardiac target organ damage (C) between body surface area-based indexing or allometric height-based indexing

BMI: body mass index; LAE: left atrial enlargement; LVH: left ventricular hypertrophy.

prevalence of almost 20% in the latter group. In that study, the level of agreement for the detection of LVH between BSAI and AHI ($k = 0.72$) was similar to that observed in this study. In contrast to our study, the level of agreement in the subgroups for BMI was not compared in that study.

It is worth noting that the use of AHI for LVM has predictive value not only at individual level but also at population level. De Simone et al. compared the population attributable risk of LVH defined by different indexing methods in the Strong Heart Study cohort and found that normalization of LVM to $H^{2.7}$ had the highest population attributable risk of cardiovascular events at follow-up, both in the total population and in the subgroup of subjects with HT. (24)

Similarly, using AHI for LAV was also shown to be superior to BSAI for the detection of LAE and prediction of events at follow-up in overweight or obese subjects. (25-27) In a sample of 127 overweight or obese subjects, of which 50% had HT, Ilijevskaja et al. observed that the frequency of LAE ranged from 15.7% to 70.1% depending on whether BSAI or AHI was used. AHI led to reclassification from normal LAV to enlarged LAV in 52.8% of subjects, with variations from 38.9% in the group with overweight to 88.2% in the group with $BMI > 40 \text{ kg/m}^2$. (25) Similar results were reported by Airale et al. in a study that included 441 hypertensive subjects; the frequency of LAE ranged from 23.4% to 50.6% using either BSAI or AHI, with a level of agreement for the detection of LAE between the two methods of $k = 0.46$. (26) In the study by Davis et al. LAE detected by AHI was independently predictive of death and cardiovascular events in all BMI groups and showed an overall performance, in terms of sensitivity and specificity, superior to BSAI across all BMI categories, including the group with $BMI < 25 \text{ kg/m}^2$. (27) The reclassification rate from normal to enlarged LA using AHI was 28.5% in the total sample and reached 55.4% in the group with $BMI > 40 \text{ kg/m}^2$. The subgroup of reclassified subjects showed an increased risk of death and cardiovascular events across all BMI categories, including those with normal or near-normal BMI. (27)

CONCLUSIONS

Overweight and obesity are growing public health issues worldwide. In Argentina, results from the most recent Cardiovascular Risk Factor Survey showed that 61.6% of the adult population is overweight, (28) and this proportion is likely to be higher in the population with HT.

Although it has been known since the 1980s that the use of weight-related parameters, such as BSA, to index cardiac structures in overweight or obese subjects has a deficit in detecting LVH and LAE compared to AHI, BSAI is still widely used in daily practice either for reasons of tradition or simplicity.

In addition to what has already been reported in the literature, the results of this study highlight the

significant discrepancy in the classification of subjects according to the presence or absence of TOD when using one indexing method or the other, which is more evident in subjects with severe obesity.

In view of the evidence provided, we must increase efforts to adapt practice to the characteristics of the population we treat. To this end, we consider it essential to include in the echocardiography equipment a calculation package appropriate to this population in order to allow the application of AHI in the parameters above mentioned, and to recommend its implementation in local clinical practice guidelines. Besides, we suggest considering the systematic use of AHI in all hypertensive subjects.

LVM and LAV indexed to BSA underestimate the presence of TOD in hypertensive overweight or obese patients, leading to an incorrect assessment of their cardiovascular risk and the therapeutic implications of this underdiagnosis. We hope this study will help to bring this issue to the forefront.

Limitations

Prevalence of LVH in our sample was lower than in other studies, probably because all subjects were on treatment and most had BP values near to normal. Reclassification of LV morphological patterns and ventricular enlargement was not evaluated due to sample size limitations. The value of the k -statistic is influenced by the prevalence of the phenomenon under study, so caution should be exercised when extrapolating the data to populations with different characteristics.

Conflicts of interest

None declared.

(See authors' conflict of interests forms on the web).

Acknowledgments

We thank Bárbara Lux and María Fernanda Ramírez Serrano for their collaboration in data collection.

REFERENCES

- Shlomain G, Grassi G, Grossman E, Mancia G. Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand? *J Clin Hypertens (Greenwich)* 2013;15:742-7. <https://doi.org/10.1111/jch.12185>
- Viazzi F, Leoncini G, Parodi D, Ratto E, Vettoretti S, Vaccaro V, et al. Impact of target organ damage assessment in the evaluation of global risk in patients with essential hypertension. *J Am Soc Nephrol* 2005;16:S89-91. <https://doi.org/10.1681/asn.2004110956>
- Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology *J Am Soc Echocardiogr* 2005;18:1440-63. <https://doi.org/10.1016/j.echo.2005.10.005>
- Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovas-

- cular Imaging. *Eur Heart J Cardiovasc. Imaging* 2015;16:233–70. <https://doi.org/10.1093/ehjci/jev014>
5. Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). *Eur Heart J Cardiovasc Imaging* 2015;16:577–605. <https://doi.org/10.1093/ehjci/jev076>
 6. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *J Hypertens* 2018;36:1953–2041. <https://doi.org/10.1097/HJH.0000000000001940>
 7. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *J Hypertens* 2023;41:1874–2071. <https://doi.org/10.1097/HJH.0000000000003480>
 8. Singh M, Sethi A, Mishra AK, Subrayappa NK, Stapleton DD, Pellikka PA. Echocardiographic Imaging Challenges in Obesity: Guideline Recommendations and Limitations of Adjusting to Body Size. *J Am Heart Assoc* 2020;9:e014609. <https://doi.org/10.1161/JAHA.119.014609>
 9. von Jeinsen B, Vasan RS, McManus DD, Mitchell GF, Cheng S, Xanthakis V. Joint influences of obesity, diabetes, and hypertension on indices of ventricular remodeling: Findings from the community-based Framingham Heart Study. *PLoS One* 2020;15:e0243199. <https://doi.org/10.1371/journal.pone.0243199>
 10. Avelar E, Cloward TV, Walker JM, Farney RJ, Strong M, Pendleton RC, et al. Left ventricular hypertrophy in severe obesity: Interactions among blood pressure, nocturnal hypoxemia, and body mass. *Hypertension* 2007;49:34–9. <https://doi.org/10.1161/01.HYP.0000251711.92482.14>
 11. Lavie CJ, Messerli FH. Cardiovascular adaptation to obesity and hypertension. *Chest* 1986;90:275–9. <https://doi.org/10.1378/chest.90.2.275>
 12. Alpert MA, Karthikeyan K, Abdullah O, Ghadban R. Obesity and Cardiac Remodeling in Adults: Mechanisms and Clinical Implications. *Prog Cardiovasc Dis* 2018;61:114–23. <https://doi.org/10.1016/j.pcad.2018.07.012>
 13. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. *J Am Coll Cardiol* 1992;20:1251–60. [https://doi.org/10.1016/0735-1097\(92\)90385-z](https://doi.org/10.1016/0735-1097(92)90385-z)
 14. de Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. *Hypertension* 1994;23:600–6. <https://doi.org/10.1161/01.hyp.23.5.600>
 15. Chirinos JA, Segers P, De Buyzere ML, Kronmal RA, Raja MW, De Bacquer D, et al. Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance. *Hypertension* 2010;56:91–8. <https://doi.org/10.1161/HYPERTENSION.110.150250>
 16. Stritzke J, Markus MR, Duderstadt S, Lieb W, Luchner A, Döring A, Keil U, et al; MONICA/KORA Investigators. The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging the MONICA/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study. *J Am Coll Cardiol* 2009;54:1982–9. <https://doi.org/10.1016/j.jacc.2009.07.034>
 17. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. *Metabolism* 2022;133:155217. <https://doi.org/10.1016/j.metabol.2022.155217>
 18. Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. *J Clin Hypertens (Greenwich)* 2013;15:14–33. <https://doi.org/10.1111/jch.12049>
 19. Kuznetsova T, Haddad F, Tikhonoff V, Kloch-Badelek M, Ryabikov A, Knez J, et al; European Project On Genes in Hypertension (EPOGH) Investigators. Impact and pitfalls of scaling of left ventricular and atrial structure in population-based studies. *J Hypertens* 2016;34:1186–94. <https://doi.org/10.1097/HJH.0000000000000922>
 20. Cuspidi C, Negri F, Muiesan ML, Capra A, Lonati L, Milan A, et al; Working Group on Heart and Hypertension, Italian Society of Hypertension. Prevalence and severity of echocardiographic left ventricular hypertrophy in hypertensive patients in clinical practice. *Blood Press* 2011;20:3–9. <https://doi.org/10.3109/08037051.2010.514713>
 21. Coca A, Gabriel R, de la Figuera M, López-Sendón JL, Fernández R, Sagastagoitia JD, et al. The impact of different echocardiographic diagnostic criteria on the prevalence of left ventricular hypertrophy in essential hypertension: the VITAE study. *Left Ventricular Arterial Tension Spain. J Hypertens* 1999;17:1471–80. <https://doi.org/10.1097/00004872-199917100-00016>
 22. Cuspidi C, Giudici V, Lonati L, Sala C, Valerio C, Mancia G. Left ventricular hypertrophy detection and body mass index in essential hypertension. *Blood Press* 2010;19:337–43. <https://doi.org/10.3109/08037051.2010.506029>
 23. Gosse P, Cremer A, Vircoulon M, Coulon P, Jan E, Papaioannou G, et al. Prognostic value of the extent of left ventricular hypertrophy and its evolution in the hypertensive patient. *J Hypertens* 2012;30:2403–9. <https://doi.org/10.1097/HJH.0b013e3283593029>
 24. de Simone G, Devereux RB. Method errors or unexplained biological information? *Hypertension* 2010;56:e177–8. <https://doi.org/10.1161/HYPERTENSIONAHA.110.163964>
 25. Ilijevska CV, Andova V, Georgievska-Ismail L. Frequency of Left Atrial Enlargement According to Different Modes of Indexing in Overweight and Obese Individuals. *Pril (Makedon Akad Nauk Umet Odd Med Nauki)* 2023;44:97–103. <https://doi.org/10.2478/prilozi-2023-0011>
 26. Airale L, Paini A, Ianniello E, Mancusi C, Moreo A, Vaudo G, et al. Left atrial volume indexed for height² is a new sensitive marker for subclinical cardiac organ damage in female hypertensive patients. *Hypertens Res* 2021;44:692–9. <https://doi.org/10.1038/s41440-021-00614-4>
 27. Davis EF, Crousillat DR, He W, Andrews CT, Hung JW, Danik JS. Indexing Left Atrial Volumes: Alternative Indexing Methods Better Predict Outcomes in Overweight and Obese Populations. *JACC Cardiovasc Imaging* 2022;15:989–97. <https://doi.org/10.1016/j.jcmg.2022.02.006>
 28. Instituto Nacional de Estadística y Censos - I.N.D.E.C. 4° Encuesta Nacional de Factores de Riesgo. Resultados definitivos. - 1a ed. 2019. Ciudad Autónoma de Buenos Aires: INDEC